Skip to main navigation menu Skip to main content Skip to site footer

Viewpoint

Vol. 150 No. 4748 (2020)

Renal replacement therapy in children and adolescents

  • Ernst Leumann
DOI
https://doi.org/10.4414/smw.2020.20371
Cite this as:
Swiss Med Wkly. 2020;150:w20371
Published
24.11.2020

References

  1. Maurer E, Neuhaus TJ, Weitz M, Kuehni CE, Laube GF. Paediatric end-stage renal disease and renal replacement therapy in Switzerland: survival and treatment trends over four decades. Swiss Med Wkly. 2020;150:w20300.
  2. Largiadèr F, Leumann E. Nierentransplantation beim Kind. Helv Chir Acta. 1972;39(1):325–9.
  3. Ambühl P. Aktuelle Erkenntnisse zur Schweizer Dialysepopulation. Hausarzt Praxis. 2017;12:22–6.
  4. Pope JC, Brock JW, Adams MC, Stephen FD, Ichikawa I. Paradigm shift from classic anatomic theories to contemporary cell biological views of CAKUT. J Am Soc Nephrol. 1999;10:2018–28.
  5. König J, Kranz B, König S, Schlingmann KP, Titieni A, Tönshoff B, et al.; Gesellschaft für Pädiatrische Nephrologie (GPN). Phenotypic spectrum of children with nephronophthisis and related ciliopathies. Clin J Am Soc Nephrol. 2017;12(12):1974–83. doi:.https://doi.org/10.2215/CJN.01280217
  6. Warejko JK, Tan W, Daga A, Schapiro D, Lawson JA, Shril S, et al. Whole exome sequencing of patients with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol. 2018;13(1):53–62. doi:.https://doi.org/10.2215/CJN.04120417
  7. Lafayette RA. Facing the vexing problem of recurrent FSGS after kidney transplantation. Clin J Am Soc Nephrol. 2020;15(2):171–3. doi:.https://doi.org/10.2215/CJN.14841219
  8. Levine AP, Chan MMY, Sadeghi-Alavijeh O, Wong EKS, Cook HT, Ashford S, et al.; MPGN/DDD/C3 Glomerulopathy Rare Disease Group; NIHR BioResource. Large-scale whole-genome sequencing reveals the genetic architecture of primary membranoproliferative GN and C3 glomerulopathy. J Am Soc Nephrol. 2020;31(2):365–73. doi:.https://doi.org/10.1681/ASN.2019040433
  9. Zuber J, Frimat M, Caillard S, Kamar N, Gatault P, Petitprez F, et al. Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2019;30(12):2449–63. doi:.https://doi.org/10.1681/ASN.2019040331